NESG lauds signing of PVP Bill which generates $2bn in five years NESG lauds signing of PVP Bill which generates $2bn in five years
Share
The Nigerian Economic Summit Group (NESG) has applauded the Nigerian Government for signing the Plant Variety Protection (PVP) Bill into law on May 21, 2021.
NESG said the implementation of the law would generate $2 billion from seed export in five years.
It can be recalled that the Plant Variety Protection Bill was passed by the House of Representatives on the 17th of December 2020 and the Nigerian Senate on the 3rd of March 2021, following several months of deliberation.
Vifor Pharma Ltd.: 93rd Vifor Pharma Group Annual General Meeting
Election of Dr. Alexandre LeBeaut and Åsa Riisberg as Independent Directors
Dividend of CHF 2.00 approved
Regulatory News:
At today s 93
rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 pandemic and in accordance with Ordinance 3 on measures to combat the coronavirus issued by the Swiss Federal Council, on the basis of Art. 8 of the new COVID-19 Act, shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 61.6% of the share capital was represented.
FG extends NIN-SIM linkage deadline to June 30, as enrollment hits 54 million tribuneonlineng.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribuneonlineng.com Daily Mail and Mail on Sunday newspapers.
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/
Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2020. CSA-AKI is a frequent complication of cardiac bypass surgery seen in about one third of patients and is associated with prolonged hospitalization, progressive kidney failure, and an increased risk of death, commented Dr. John Neylan, Angion s Senior Vice President and Chief Medical Officer. Currently, there are no approved therapies to prevent this serious condition. Thi
Vifor Pharma: First patient enrolled in CARE-HK in HF to evaluate role of Veltassa (patiromer) in enabling RAASi treatment finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.